Podophyllotoxin (International)
Scheme
BAN
ATC (Anatomical Therapeutic Chemical Classification)
D06BB04
CAS registry number (Chemical Abstracts Service)
0000518-28-5
Chemical Formula
C22-H22-O8
Molecular Weight
414
Therapeutic Categories
Dermatological agent
Topical antimitotic agent
Topical cytostatic agent
Chemical Name
Furo[3',4':6,7]naphto[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimetoxyphenyl)-, [5R-(5α,5aβ,8aα,9α)]-
Foreign Names
- Podophyllotoxinum (Latin)
- Podophyllotoxin (German)
- Podophyllotoxine (French)
Generic Names
- Podofilox (OS: USAN)
- Podophyllotoxin (OS: BAN)
- Podophyllotoxine (OS: DCF)
- Podophyllotoxin (PH: Ph. Helv. 11)
Brand Names
- Condilom
Bussié, Colombia; Bussié, Honduras - Condiver
Lacico, Colombia - Condylin
Takeda Austria, Bulgaria - Condyline
2care4, Norway; Astellas, Italy; Astellas, Kuwait; BModesto, Netherlands; Famar, Georgia; Galderma, Norway; Galderma Nordic, Denmark; Galderma Nordic, Sweden; Galderma Nordic AB, Finland; Galderma Nordic AB, Iceland; LEO Pharma, Netherlands; LEO Pharma, New Zealand; LEO Pharma, Poland; LEO Pharma, Romania; Medcor Pharmaceuticals, Netherlands; Orifarm, Norway; Sanofi-Aventis, Canada; Takeda, Australia; Takeda, Ireland; Takeda Pharma, Switzerland; Takeda UK, United Kingdom - Condyline 0.5%
LEO Pharma, France - Condyline 5 mg/ml
Takeda, Hungary - Condylox
Allergan, United States; Dr. August Wolff, Germany; Takeda, Israel; Tianjin Takeda Pharmaceutical, China - Condylox 0.5%
Takeda Pharma, Austria - Podofilm
Assos, Turkey; Paladin, Canada; Pharmascience, Hong Kong - Podofilox
Paddock Laboratories, United States - Podox 0.5%
Bussié, Colombia; Bussié, Dominican Republic; Bussié, Guatemala; Bussié, Honduras - Podoxin
Cassara, Argentina; Promofarma, Uruguay - Posalfilin [+ Salicylic acid]
Norgine, New Zealand - Wartec
BModesto, Netherlands; Dr. Fisher Farma, Netherlands; Euro Registratie, Netherlands; GlaxoSmithKline, Denmark; GlaxoSmithKline, Finland; GlaxoSmithKline, Lithuania; GlaxoSmithKline, Latvia; GlaxoSmithKline, Sweden; GlaxoSmithKline A.B.E.E., Greece; GlaxoSmithKline Australia, Australia; GSK, Czech Republic; Medcor Pharmaceuticals, Netherlands; Phoenix Labs, Netherlands; Stiefel, Brazil; Stiefel, China; Stiefel, Estonia; Stiefel, Spain; Stiefel, Hong Kong; Stiefel, Italy; Stiefel, Lebanon; Stiefel, Mexico; Stiefel, Oman; Stiefel, Romania; Stiefel, Slovakia; Stiefel, Taiwan; Stiefel, South Africa; Stiefel Laboratories Polska Sp. z.o.o., Poland - Wartec 0.15%
GlaxoSmithKline, Germany; GlaxoSmithKline, Finland; GlaxoSmithKline A.B.E.E., Greece; Stiefel, Germany - Wartec 0.5%
GlaxoSmithKline A.B.E.E., Greece - Warticon
Stiefel, United Kingdom; Stiefel, Ireland - Warticon 0.5%
GlaxoSmithKline, Cyprus - You Tuo Xin
Huawei Pharmaceutical, China
Glossary
| Term | Definition |
|---|---|
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| USAN | United States Adopted Name |
Further information on drug naming conventions: International Nonproprietary Names.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.